Haleos Labs Limited has announced the reopening of a special window for shareholders to re-lodge physical share transfer requests that were previously rejected or not processed due to documentation deficiencies.

Special Window Details

The company has informed stock exchanges that a special window will remain open for one year, from February 5, 2026 to February 4, 2027. This facility is specifically designed for transfer deeds that were lodged prior to the April 1, 2019 deadline but were either rejected, returned, or not processed due to deficiencies in documentation or other procedural lapses.

Regulatory Framework

The initiative follows SEBI circular no. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The company's announcement, signed by Company Secretary Trupti Ranjan Mohanty, was communicated to both BSE Limited and National Stock Exchange of India Limited on February 28, 2026.

Shareholder Benefits

Shareholders who missed the earlier deadline of January 6, 2026 are encouraged to utilize this opportunity by furnishing necessary documents to the company or its Registrar and Share Transfer Agent, M/s. Purva Sharegistry (India) Private Limited. The company emphasizes that all such transfers will be processed exclusively in demat mode and will be subject to a one-year lock-in period from the date of dematerialization.

Dividend Reminder

The company has also reminded shareholders to claim their unclaimed dividends at the earliest. If dividends remain unclaimed for seven years, both the dividend amount and corresponding shares will be transferred to the Investor Education & Protection Fund Authority (IEPFA).

Company Information

Haleos Labs Limited, formerly known as SMS Lifesciences India Limited, operates from its registered office at Plot No. 19-III, Road No. 71, Opp. Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad-500 096, Telangana. The company can be contacted at +91-40-6628 888 or through info@haleoslabs.com .

SMS Lifesciences India Limited , a prominent player in the pharmaceutical sector, has announced a significant corporate rebranding. The company has officially changed its name to Haleos Labs Limited, marking a new chapter in its corporate identity.

Key Details of the Name Change

Approval Process

The name change follows a comprehensive approval process, ensuring compliance with all regulatory requirements:

1. Board Approval
2. Shareholders' Approval
3. Ministry of Corporate Affairs (MCA) Approval
4. National Stock Exchange (NSE) Approval
5. Bombay Stock Exchange (BSE) Approval

Impact on Company Operations

It's important to note that this rebranding initiative is primarily a change in corporate identity. The company has clarified that:

• The legal status of the company remains unaltered
• The Corporate Identification Number (CIN) remains unchanged
• There is no impact on the company's day-to-day operations

Investor Implications

For investors and stakeholders, the primary change will be in the company's representation on stock exchanges. The new trading symbol 'HALEOSLABS' will replace the previous 'SMSLIFE' on both the National Stock Exchange and the Bombay Stock Exchange.

This corporate action reflects the company's evolution and potentially its future strategic direction. While the core business operations remain unchanged, the new brand identity might signal the company's aspirations or a shift in its market positioning.

Investors and market participants should take note of this change to avoid any confusion in their trading or investment activities. It's advisable to update any automated trading systems or watchlists to reflect the new trading symbol.

As with any significant corporate change, stakeholders should monitor for any subsequent announcements or changes that might follow this rebranding exercise.